

# Takayuki Ueno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6740880/publications.pdf>

Version: 2024-02-01

93  
papers

1,376  
citations

516215

16  
h-index

377514

34  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2011  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 519-530.	5.1	441
2	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1298-1306.	3.0	83
3	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
4	Interobserver concordance of Ki67 labeling index in breast cancer: a pan breast cancer research group Ki67 RCTing Study. <i>Cancer Science</i> , 2013, 104, 1539-1543.	1.7	65
5	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. <i>BMC Medicine</i> , 2022, 20, 105.	2.3	60
6	Evaluating the 21-gene assay Recurrence Score <sup>®</sup> as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 607-613.	1.0	54
7	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. <i>Cancer Science</i> , 2011, 102, 858-865.	1.7	44
8	Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. <i>BMC Cancer</i> , 2016, 16, 230.	1.1	30
9	Treating HR+/HER2 <sup>-</sup> breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	1.1	29
10	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 1-25.	1.4	29
11	Serial measurement of serum S-100B protein as a marker of cerebral damage after cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2003, 75, 1892-1897.	0.7	28
12	Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. <i>European Journal of Cancer</i> , 2011, 47, 2265-2272.	1.3	27
13	Risk Factors for Skin Flap Necrosis in Breast Cancer Patients Treated with Mastectomy Followed by Immediate Breast Reconstruction. <i>World Journal of Surgery</i> , 2019, 43, 846-852.	0.8	24
14	Genome-wide copy number analysis in primary breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S31-S35.	1.5	22
15	Penetrating Atherosclerotic Ulcer. <i>Surgery Today</i> , 2001, 31, 32-35.	0.7	20
16	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. <i>ESMO Open</i> , 2019, 4, e000476.	2.0	17
17	Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 331-341.	1.1	17
18	Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. <i>International Journal of Molecular Sciences</i> , 2019, 20, 984.	1.8	16
20	Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 74-84.	5.1	16
21	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. <i>ESMO Open</i> , 2018, 3, e000314.	2.0	15
22	Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. <i>Cancer Science</i> , 2021, 112, 454-464.	1.7	15
23	Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. <i>Breast</i> , 2012, 21, 40-45.	0.9	14
24	The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. <i>Npj Precision Oncology</i> , 2017, 1, 6.	2.3	13
25	GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	12
26	Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence. <i>Radiation Oncology</i> , 2019, 14, 159.	1.2	11
27	A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018, 7, 2442-2451.	1.3	10
28	Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. <i>Cancer Medicine</i> , 2018, 7, 3044-3056.	1.3	10
29	Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. <i>Pathology Research and Practice</i> , 2020, 216, 152750.	1.0	10
30	Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. <i>Cancer Science</i> , 2022, 113, 1808-1820.	1.7	10
31	The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer. <i>Cancer Science</i> , 2022, 113, 2336-2351.	1.7	10
32	A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S <sup>1</sup> for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the Tj ETQq0130 rgBT / Overlock 1	1.0	10
33	Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. <i>Journal of Radiation Research</i> , 2020, 61, 440-446.	0.8	8
34	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
35	Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 103-111.	1.1	7
36	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 3-11.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. <i>BMC Medicine</i> , 2022, 20, 136.	2.3	7
38	A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-MO5 PRECIOUS study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 855-859.	0.6	6
39	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. <i>Scientific Reports</i> , 2020, 10, 11203.	1.6	6
40	Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment Center. <i>Cancer Cell</i> , 2021, 39, 9-10.	7.7	6
41	Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 78.	0.4	6
42	Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881102.	0.8	5
43	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype. <i>Scientific Reports</i> , 2021, 11, 10858.	1.6	5
44	Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. <i>Cancer Medicine</i> , 2019, 8, 5468-5481.	1.3	4
45	Local management after neoadjuvant treatment for breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 34-34.	0.4	4
46	Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 13-21.	1.4	4
47	Myofibroblastoma of the breast showing rare palisaded morphology and uncommon desmin and CD34-negative immunophenotype: A case report. <i>Pathology International</i> , 2021, 71, 548-555.	0.6	4
48	Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis. <i>BMC Cancer</i> , 2020, 20, 932.	1.1	4
49	Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. <i>BMC Cancer</i> , 2022, 22, 36.	1.1	4
50	Breast MR Image Fusion by Deformable Implicit Polynomial (DIP). <i>IPSJ Transactions on Computer Vision and Applications</i> , 2013, 5, 99-103.	4.4	3
51	Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society. <i>Breast Cancer</i> , 2017, 24, 427-432.	1.3	3
52	Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. <i>Cancer Science</i> , 2021, 112, 1310-1319.	1.7	3
53	Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial). , 2020, , .		3
54	Assessment of a cancer genomic profile test for patients with metastatic breast cancer. <i>Scientific Reports</i> , 2022, 12, 4813.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Surgical Management of Metastatic Breast Cancer: A Mini Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
56	Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 35-35.	0.4	2
57	Abstract PD7-05: A multicenter prospective study to predict pathologic complete response by vacuum-assisted breast biopsy based on MRI and US findings after neoadjuvant chemotherapy. <i>Cancer Research</i> , 2022, 82, PD7-05-PD7-05.	0.4	2
58	Comment and reply on: Vasohibin-1 and its emerging role in the evolution and progression of systemic tumors besides renal cell carcinomas. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 105-106.	1.5	1
59	Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 2633.	1.7	1
60	Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. , 2021, , .		1
61	Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1026-1026.	0.8	1
62	Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12094-e12094.	0.8	1
63	Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1075-1075.	0.8	1
64	Abstract P5-01-22: Genomic landscape of circulating tumor DNA in early-stage breast cancer. <i>Cancer Research</i> , 2020, 80, P5-01-22-P5-01-22.	0.4	1
65	International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1025-1025.	0.8	1
66	Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial). , 2020, , .		1
67	Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC). <i>Breast Cancer</i> , 0, , .	1.3	1
68	PO130 CLINICAL UTILITY OF THE EXPRESSION OF HER3, HER4, PTEN AND IGF1R IN HER2-POSITIVE ADVANCED OR METASTATIC BREAST CANCER. <i>Breast</i> , 2015, 24, S66.	0.9	0
69	Only a few young patients aged 40 years with "high-risk"™ breast cancer preserved fertility; report from actual survey in a Japanese cancer hospital. <i>Breast</i> , 2018, 41, S26-S27.	0.9	0
70	Characteristics and prognosis of leptomeningeal metastasis in patients with breast cancer. <i>Annals of Oncology</i> , 2019, 30, vi113.	0.6	0
71	Response to Sung, Rosenberg, and Yang. <i>Journal of the National Cancer Institute</i> , 2020, 112, 547-548.	3.0	0
72	Focused issue "Neoadjuvant/adjuvant treatment for early breast cancer" Chinese Clinical Oncology, 2020, 9, 26-26.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Breast castleman disease. Breast Journal, 2020, 26, 1855-1856.	0.4	0
74	Abstract PS1-19: The accuracy of axillary node assessment of ultrasound after neoadjuvant chemotherapy in clinically node positive patients. , 2021, , .		0
75	Abstract PS2-32: Incidental malignant findings on pre-admission chest computed tomography scan for coronavirus disease screening in patients with breast cancer or other cancers. , 2021, , .		0
76	Impact of body mass index on the prognosis of Japanese women with operable hormone receptor-positive breast cancer: A single institutional retrospective study.. Journal of Clinical Oncology, 2021, 39, e12547-e12547.	0.8	0
77	MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer. Annals of Oncology, 2021, 32, S320.	0.6	0
78	Ultrasonographic imaging of invasive ductal carcinoma linked to revision of the histological classification of breast tumors. Choonpa Igaku, 2021, 48, 241-247.	0.0	0
79	Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues.. Journal of Clinical Oncology, 2013, 31, 571-571.	0.8	0
80	Primary mediastinal germ cell tumor with absent elevation of AFP at recurrence; a case report.. The Journal of the Japanese Association for Chest Surgery, 1997, 11, 186-193.	0.0	0
81	Abstract OT1-3-01: Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components. , 2015, , .		0
82	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. Journal of Clinical Oncology, 2016, 34, TPS636-TPS636.	0.8	0
83	Phase II study on radiofrequency ablation in early breast cancer.. Journal of Clinical Oncology, 2016, 34, e12536-e12536.	0.8	0
84	Abstract 4138: Immunological profile of metastatic or recurrent breast cancer patients. , 2016, , .		0
85	Abstract 3484: Analysis of in situ expression of hormone receptors and proliferation marker at a single cell level in breast cancer tissues. , 2016, , .		0
86	Utility of Repeat Sentinel Lymph Node Biopsy for cNO Ipsilateral Breast Tumor Recurrence in Patients Initially Treated with Breast-Conserving Surgery and Sentinel Lymph Node Biopsy. SSRN Electronic Journal, 0, , .	0.4	0
87	Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer. , 2020, , .		0
88	Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.. Journal of Clinical Oncology, 2020, 38, 532-532.	0.8	0
89	Monitoring of therapeutic efficacy to CDK4/6 inhibitors and early detection of metastatic relapse in breast cancer by ultra-deep sequencing of plasma cell-free DNA.. Journal of Clinical Oncology, 2020, 38, e15544-e15544.	0.8	0
90	Abstract A29: Next-generation sequencing of circulating tumor DNA to monitor treatment response to CDK4/6 inhibitors in breast cancer. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
91	A Case of Primary Breast Angiosarcoma in a 20-year-old Woman. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 2432-2436.	0.0	0
92	Abstract P1-15-02: Low incidence of hepatitis B reactivation after chemotherapy in Japanese breast cancer patients with resolved HBV. Cancer Research, 2022, 82, P1-15-02-P1-15-02.	0.4	0
93	Abstract P4-11-06: Effect of suppressed ovarian function on prognosis of premenopausal obese women with hormone receptor-positive breast cancer: A single-institute retrospective study. Cancer Research, 2022, 82, P4-11-06-P4-11-06.	0.4	0